Zacks Investment Research on MSN

QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test

Last week, QuidelOrtho Corporation QDEL announced the availability of QUICKVUE Influenza + SARS Test. The CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay is the latest addition to the ...
Morningstar

QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use

SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of ...